- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03930771
Recruitment Status Active, not recruiting
First Posted April 29, 2019
Last update posted May 29, 2020
This is an open label study to assess the efficacy of capecitabine (CAP) and temozolomide (TMZ) in recurrent pituitary adenomas. There will be a safety run-in of at least three patients to establish any dose limiting toxicities. Enrolled patients will receive treatment in 28-day cycles: capecitabine 1500mg/m2 per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14 and oral temozolomide 150 to 200 mg/m2 on days 10 through 14. This will be followed by 14 days off treatment. MRI imaging will be completed after every two cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
|Experimental: All Patients
All subjects will receive: Capecitabine (oral 5-Fluorouracil) 1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14. Temozolomide (second generation alkylating agent) 150 to 200 mg/m2 orally on days 10 through 14. After completion of 6 cycles, patients achieving a complete or partial tumor response may continue to receive capecitabine temozolomide at the investigator's discretion in the absence of disease progression or unacceptable toxicity. Patients will be monitored for six months after they come off the study (either after completing 6 cycles or in setting of disease progression or unacceptable toxicity).
1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
150 to 200 mg/m2 orally on days 10 through 14.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
- Male or female ≥ 18 years of age.
- Patients with nonfunctioning tumors must have histologically confirmed pituitary
adenoma. Patients with functioning tumors do not require surgery if there is clear
diagnosis of functioning pituitary adenomas established based on endocrine evaluation.
- Karnofsky performance status ≥ 70%.
- Life expectancy of greater than six months.
- Residual or recurrent pituitary adenoma ≥1cm in maximal diameter on MRI Brain; patient
must have received at least one prior therapy, such as surgery, radiation and/or
- Patients must have normal organ and marrow function as defined below. NOTE: Laboratory
values must be taken within 7 days prior to chemotherapy administration. Transfusions
and/or growth factor support may not be used to meet this criteria):
- Platelet count ≥ 100 × 109/L.
- Hemoglobin ≥ 9 g/dL.
- WBC ≥ 3 × 109/L
- Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.
- Serum bilirubin ≤ 1.5 × upper limit of normal (ULN) or ≤ 3 x ULN if Gilbert's disease
- Aspartate transaminase (AST) ≤ 2.5 ULN.
- Alanine transaminase (ALT) ≤ 2.5 ULN.
- Serum creatinine ≤ 1.5 × ULN OR creatinine clearance≥60mL/min/1.73 m2 for patients
with creatinine levels above institutional normal.
- Patients must be able to undergo a MRI Brain/Pituitary
- For women of child-bearing potential and for men with partners of child-bearing
potential, subject must agree to take contraceptive measures for duration of treatment
and at least 6 months after the last dose of chemotherapy.
- Patients must have the ability to understand and the willingness to sign a written
informed consent document.
- Prior temozolomide and/or capecitabine therapy for treatment of the pituitary tumor.
- Other active malignancy outside of nonmelanoma skin cancer (patients in remission and
with prior treatment more than two years ago will be accepted into trial).
- Clinically significant renal, hematologic or hepatic abnormalities.
- Use of Vitamin K antagonists such as warfarin (concentrations may be altered by
concomitant use of capecitabine)
- Uncontrolled concurrent illness including, but not limited to, ongoing or active
infection requiring IV antibiotics & psychiatric illness/social situations that would
limit compliance with study requirements
- History of deficient dihydropyrimidine dehydrogenase activity.
- History of immunodeficiency.
- Patients who are taking any other concurrent investigational therapy.
- Patients who are pregnant or breastfeeding.
- Patients who have had prior radiation treatment in the last six months
- Patients who have had prior pituitary surgery within the last two months
United States, New York
Weill Cornell Medical College
Weill Medical College of Cornell University
Principal Investigator: Rajiv Magge, MD Weill Medical College of Cornell University